Similar articles

• ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK.

  Kotseva K, Jennings CS, Turner EL, Mead A, Connolly S, Jones J, Bowker TJ, Wood DA; ASPIRE-2-PREVENT Study Group. Kotseva K, et al. Heart. 2012 Jun;98(11):865-71. doi: 10.1136/heartjnl-2011-301603. Heart. 2012. PMID: 22581735
• Coronary risk versus cardiovascular risk for treatment decisions in mild hypertension.

  Yeo WW, Yeo KR. Yeo WW, et al. J Cardiovasc Risk. 2002 Oct;9(5):275-80. doi: 10.1177/174182670200900508. J Cardiovasc Risk. 2002. PMID: 12394321
• [Initial management of hypertension in a primary care service].

  Nardo P, Bovier P, Pechère-Bertschi A. Nardo P, et al. Rev Med Suisse. 2006 Sep 13;2(78):2024-6, 2029-34. Rev Med Suisse. 2006. PMID: 17019837 French.
• [Effect of antihypertensive drug treatment on the incidence of cardiovascular morbidity and mortality in mild arterial hypertension].

  Tomov I. Tomov I. Vutr Boles. 1985;24(6):39-47. Vutr Boles. 1985. PMID: 3913145 Review. Bulgarian. No abstract available.
• [Blood pressure goal and choice of antihypertensive treatment in patients with mild hypertensive cardiovascular disease].

  Narumi H, Takano H, Komuro I. Narumi H, et al. Nihon Rinsho. 2008 Aug;66(8):1566-73. Nihon Rinsho. 2008. PMID: 18700559 Review. Japanese.